Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Evaxion Biotech A/S ADR (EVAX)

Evaxion Biotech A/S ADR (EVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,051
  • Shares Outstanding, K 23,834
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,530 K
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.45
Trade EVAX with:

Options Overview Details

View History
  • Implied Volatility 114.20% ( +8.78%)
  • Historical Volatility 56.22%
  • IV Percentile 48%
  • IV Rank 17.83%
  • IV High 637.79% on 11/18/22
  • IV Low 0.56% on 07/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 3,440

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +28.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 unch
on 11/25/22
2.72 -22.79%
on 10/27/22
-0.54 (-20.45%)
since 10/25/22
3-Month
1.90 +10.53%
on 09/20/22
3.52 -40.34%
on 09/21/22
-0.44 (-17.32%)
since 08/25/22
52-Week
1.51 +39.06%
on 05/12/22
5.02 -58.13%
on 11/26/21
-2.97 (-58.58%)
since 11/24/21

Most Recent Stories

More News
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

MRK : 107.50 (+0.64%)
APTO : 0.7019 (+4.78%)
ORIC : 3.50 (-3.58%)
EVAX : 2.10 (-1.18%)
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for...

EVAX : 2.10 (-1.18%)
Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

COPENHAGEN, Denmark, July 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 2.10 (-1.18%)
Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 2.10 (-1.18%)
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 2.10 (-1.18%)
Bears are Losing Control Over Evaxion Biotech AS Sponsored ADR (EVAX), Here's Why It's a 'Buy' Now

Evaxion Biotech AS Sponsored ADR (EVAX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong...

EVAX : 2.10 (-1.18%)
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital

COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 2.10 (-1.18%)
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a...

EVAX : 2.10 (-1.18%)
Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

COPENHAGEN, Denmark, April 29, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...

EVAX : 2.10 (-1.18%)
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of...

EVAX : 2.10 (-1.18%)
PSNL : 2.55 (+1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and infectious diseases. Evaxion Biotech A/S is based in COPENHAGEN, Denmark.

See More

Key Turning Points

3rd Resistance Point 2.25
2nd Resistance Point 2.22
1st Resistance Point 2.16
Last Price 2.10
1st Support Level 2.07
2nd Support Level 2.04
3rd Support Level 1.98

See More

52-Week High 5.02
Fibonacci 61.8% 3.68
Fibonacci 50% 3.26
Fibonacci 38.2% 2.85
Last Price 2.10
52-Week Low 1.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar